1. Home
  2. ATCX vs GBIO Comparison

ATCX vs GBIO Comparison

Compare ATCX & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ATCX

Atlas Critical Minerals Corporation Common Stock

N/A

Current Price

$8.18

Market Cap

31.8M

Sector

N/A

ML Signal

N/A

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.70

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATCX
GBIO
Founded
2016
2016
Country
Brazil
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.8M
36.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ATCX
GBIO
Price
$8.18
$5.70
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$8.88
AVG Volume (30 Days)
35.6K
71.9K
Earning Date
03-16-2023
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$367,030.00
$15,270,000.00
Revenue This Year
$109,631.07
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.80
$3.00
52 Week High
$47.16
$10.40

Technical Indicators

Market Signals
Indicator
ATCX
GBIO
Relative Strength Index (RSI) N/A 58.58
Support Level N/A $5.31
Resistance Level N/A $5.70
Average True Range (ATR) 0.00 0.17
MACD 0.00 0.02
Stochastic Oscillator 0.00 76.09

Price Performance

Historical Comparison
ATCX
GBIO

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: